Welcome to BeiMedPlus

Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton's tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).

Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.

Poster presented at EHA2022 exploring the potential of PD-1 inhibition for relapsed/refractory (R/R) mature T- and NK-cell neoplasms.

Poster presented at EHA2022 describing treatment of Waldenström's macroglobulinemia (WM) by inhibiting Bruton's tyrosine kinase (BTKi).

Inhibiting BTK in older patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).